Safety and Tolerability of Escalating Cannabinoid Doses in Healthy Cats

Overview

Journal J Feline Med Surg

Specialty Veterinary Medicine

Date 2021 Mar 26

PMID 33769105

Citations 16

Authors

Justyna E Kulpa

Lina J Paulionis

Graham Ml Eglit

Dana M Vaughn

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to determine the safety and tolerability of escalating doses of orally delivered cannabis oils predominant in cannabidiol (CBD), tetrahydrocannabinol (THC), or both CBD and THC in healthy cats.

Methods: In this placebo-controlled, blinded study, 20 healthy adult cats were randomized to one of five treatment groups (n = 4 per group): two placebo groups (sunflower oil [SF] or medium-chain triglyceride oil [MCT]), or three plant-derived cannabinoid oil groups (CBD in MCT, THC in MCT or CBD/THC [1.5:1] in SF). Up to 11 escalating doses of each formulation were delivered orally via syringe to fasted subjects, with at least 3 days separating doses. Safety and tolerability were determined from clinical observations, complete blood counts (CBCs) and clinical chemistry. Plasma cannabinoids (CBD, THC) and metabolites (7-COOH-CBD, 11-OH-THC) were assessed.

Results: Titration to maximum doses of 30.5 mg/kg CBD (CBD oil), 41.5 mg/kg THC (THC oil) or 13.0:8.4 mg/kg CBD:THC (CBD/THC oil) was safely achieved in all subjects. All observed adverse events (AEs) were mild, transient and resolved without medical intervention. Gastrointestinal AEs were more common with formulations containing MCT. Constitutional (lethargy, hypothermia), neurologic (ataxia) and ocular (protrusion membrana nictitans) AEs were more common with oils containing THC (CBD/THC and THC oils). There were no clinically significant changes in CBC or clinical chemistry across treatment groups. Higher plasma levels of the cannabinoids and their metabolites following administration of the CBD/THC combination product are suggestive of a pharmacokinetic interaction.

Conclusions And Relevance: This is the first feline study to explore the safety and tolerability of CBD and THC, alone and in combination, in a controlled research setting. These findings will inform veterinarians of the safety profile of cannabinoids, particularly when considering the potential therapeutic use of CBD in cats or recognizing clinical signs associated with accidental exposure to THC-containing products.

Citing Articles

CBD for pets: navigating quality assurance, safety standards, and marketing strategies.

Rideout H, Cook A, Whetton A J Cannabis Res. 2025; 7(1):6.

PMID: 39849662 PMC: 11755934. DOI: 10.1186/s42238-024-00257-5.

Investigating the effect a single dose of cannabidiol has on measures of stress in cats when being transported in a carrier and meeting a novel person in an unfamiliar environment.

Weller J, Flint H, Hunt A, Ellerby Z, King T Front Vet Sci. 2024; 11:1476296.

PMID: 39559539 PMC: 11571322. DOI: 10.3389/fvets.2024.1476296.

in veterinary medicine: Foundations and therapeutic applications.

Pinto K, Requicha J Can Vet J. 2024; 65(9):948-958.

PMID: 39219599 PMC: 11339888.

Perioperative Analgesic and Sedative Effects of Cannabidiol in Cats Undergoing Ovariohysterectomy.

Zanelli G, Vieira G, Souza R, Aguiar A, Cassu R Animals (Basel). 2024; 14(16).

PMID: 39199820 PMC: 11350847. DOI: 10.3390/ani14162286.

Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review.

Di Salvo A, Chiaradia E, Sforna M, Rocca G Vet Res Commun. 2024; 48(5):2915-2941.

PMID: 39162768 PMC: 11442603. DOI: 10.1007/s11259-024-10509-7.

References

Colasanti B, Brown R, Craig C . Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol. 1984; 15(6):479-84. DOI: 10.1016/0306-3623(84)90202-7. View

Verrico C, Wesson S, Konduri V, Hofferek C, Vazquez-Perez J, Blair E . A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. 2020; 161(9):2191-2202. PMC: 7584779. DOI: 10.1097/j.pain.0000000000001896. View

Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K . Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res. 2007; 1188:157-64. DOI: 10.1016/j.brainres.2007.09.090. View

Gamble L, Boesch J, Frye C, Schwark W, Mann S, Wolfe L . Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Front Vet Sci. 2018; 5:165. PMC: 6065210. DOI: 10.3389/fvets.2018.00165. View

Zuardi A, Karniol I . Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res. 1983; 16(2):141-6. View

Quimby J, Smith M, Lunn K . Evaluation of the effects of hospital visit stress on physiologic parameters in the cat. J Feline Med Surg. 2011; 13(10):733-7. PMC: 10832771. DOI: 10.1016/j.jfms.2011.07.003. View

Grigg E, Kogan L, van Haaften K, Kolus C . Cat owners' perceptions of psychoactive medications, supplements and pheromones for the treatment of feline behavior problems. J Feline Med Surg. 2018; 21(10):902-909. PMC: 11132244. DOI: 10.1177/1098612X18807783. View

. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2017; 14(4):417-446. DOI: 10.1111/vco.283. View

Janeczek A, Zawadzki M, Szpot P, Niedzwiedz A . Marijuana intoxication in a cat. Acta Vet Scand. 2018; 60(1):44. PMC: 6042427. DOI: 10.1186/s13028-018-0398-0. View

10.

Korczyn A . The ocular effects of cannabinoids. Gen Pharmacol. 1980; 11(5):419-23. DOI: 10.1016/0306-3623(80)90026-9. View

11.

Brutlag A, Hommerding H . Toxicology of Marijuana, Synthetic Cannabinoids, and Cannabidiol in Dogs and Cats. Vet Clin North Am Small Anim Pract. 2018; 48(6):1087-1102. DOI: 10.1016/j.cvsm.2018.07.008. View

12.

Fernandes M, Schabarek A, Coper H, Hill R . Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia. 1974; 38(4):329-38. DOI: 10.1007/BF00429130. View

13.

Taffe M, Creehan K, Vandewater S . Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats. Br J Pharmacol. 2014; 172(7):1783-91. PMC: 4376456. DOI: 10.1111/bph.13024. View

14.

Hollister L, Gillespie H . Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol. Clin Pharmacol Ther. 1975; 18(1):80-3. DOI: 10.1002/cpt197518180. View

15.

Brioschi F, Di Cesare F, Gioeni D, Rabbogliatti V, Ferrari F, DUrso E . Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis. Animals (Basel). 2020; 10(9). PMC: 7552307. DOI: 10.3390/ani10091505. View

16.

Iffland K, Grotenhermen F . An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017; 2(1):139-154. PMC: 5569602. DOI: 10.1089/can.2016.0034. View

17.

McGrath S, Bartner L, Rao S, Packer R, Gustafson D . Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. 2019; 254(11):1301-1308. DOI: 10.2460/javma.254.11.1301. View

18.

Colasanti B, Powell S, Craig C . Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene. Exp Eye Res. 1984; 38(1):63-71. DOI: 10.1016/0014-4835(84)90139-8. View

19.

Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T . Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl). 2011; 218(2):443-57. DOI: 10.1007/s00213-011-2342-0. View

20.

Zuardi A, Hallak J, Crippa J . Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl). 2011; 219(1):247-9. DOI: 10.1007/s00213-011-2495-x. View